BioTherapeutics, which is a unit of the Baxter’s BioScience business, focuses on three key therapeutic areas: immunoglobulin therapy, pulmonology, and critical care therapies. Our global commitment is to be a partner with the healthcare community, provide therapies that advance patient care, and enable the achievement of outcomes through innovation, science and technology. BioTherapeutics aims to achieve this every day through our broad portfolio of therapeutic brands.
BioTherapeutics’ products include plasma-based Intravenous Immunoglobulins (IVIG) therapies used to treat primary and secondary immunodeficiency (PI and SI) disorders. In addition, Baxter produces treatments for alpha-1 antitrypsin deficiency (AATD), immune thrombocytopenic purpura (ITP), severe congenital Protein C deficiency, and albumin. These products are used as plasma-volume replacement therapy for the treatment of hypovolemia and provide adequate fluid volume and pressure for critically ill patients. BioTherapeutics also offers comprehensive customer/patient programs and services, as well as plasma collection capabilities, and manufactures safe and effective products.
BioTherapeutics Research and Development pipeline is investigating use for IVIG therapies in immunology and neurological disorders [Alzheimer's disease and multifocal motor neuropathy (MMN)]. Also being investigated are new delivery forms such as subcutaneous administration.
Historic Overview |
With more than 75 years in specialty biologic therapies, Baxter’s BioScience business is a market leader in the areas of vaccines and blood-based disorders such as hemophilia, as well as BioTherapeutics for immunodeficiencies and other chronic and acute conditions. |
Leadership |
Joy A. Amundson, Corporate Vice President - President, BioScience |
Global Market Presence |
More than 100 countries |
Therapeutic focus |
ImmunoglobulinsPulmonology and Critical Care
|
Research and development |
BioTherapeutics InnovationBaxter’s BioScience business is investigating IVIG in the treatment of neurological disorders (Alzheimer's disease and MMN). Baxter’s BioScience business, in conjunction with Halozyme Therapeutics, is studying the subcutaneous administration of IVIG. |
Manufacturing and operations |
Manufacturing
Operations
|
A sterile, nonpyrogenic preparation of albumin in a single-dosage
Sterile, stable, lyophilized preparation of purified alpha 1-proteinase inhibitor
